Revenue
2021
2022
2023
2024
2025
ARS Pharmaceuticals, Inc. (SPRY)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $84.3M | $89.1M | $30,000 | $1.3M | $5.5M | — |
| Research & development | $13.2M | $19.6M | $20.3M | $18.4M | $20.3M | $24.6M |
| Operating expenses | $263.7M | $92.2M | $67.5M | $36.8M | $25.0M | $32.9M |
| Operating income | −$179.4M | −$3.1M | −$67.5M | −$35.5M | −$19.5M | −$32.9M |
| EBITDAderived | −$178.1M | −$3.0M | −$67.4M | −$35.2M | −$19.2M | — |
| Net income | −$171.3M | $8.0M | −$54.4M | −$34.7M | −$20.2M | −$32.9M |
| Basic EPSper diluted share | -$1.74 | $0.08 | -$0.57 | -$0.87 | -$0.70 | -$11.33 |
| Diluted EPSper diluted share | -$1.74 | $0.08 | -$0.57 | -$0.87 | -$0.70 | -$11.33 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 12, 2026Form 4 · 10b5-1 | Karas EricChief Commercial Officer | SellCommon Stock | 25.0K | $10.00 | $250.0K | 12.2K |
| Jun 12, 2026Form 4 · 10b5-1 | Fitzpatrick Alexander AChief Legal Officer | SellCommon Stock | 3.4K | $10.00 | $33.5K | 90.9K |
| Nov 13, 2025Form 4 | Dorsey BrianChief Operating Officer | SellCommon Stock | 21.8K | $8.71 | $190.1K | 10.8K |
| Nov 12, 2025Form 4 | Chakma JustinChief Business Officer | SellCommon Stock | 136.4K | $8.86 | $1.21M | 0 |
| Nov 12, 2025Form 4 | Chakma JustinChief Business Officer | SellCommon Stock | 30.0K | $8.91 | $267.3K | 136.4K |